Staidson recently issued a performance forecast, indicating an expected net loss for 2025. This projection is primarily attributed to increased R&D investments, intensified market competition, and the fact that several drugs in the pipeline have not yet generated commercial returns. As a biopharmaceutical company focused on treatments for neurological damage and autoimmune diseases, Staidson has long been dedicated to innovative drug development. However, high capital investment and extended R&D cycles may lead to periodic losses. Although short-term profitability is under pressure, core products such as STSG-0002 are still in clinical advancement, and future approvals could potentially improve performance. Investors should monitor R&D progress and liquidity conditions to rationally assess long-term value and risks.
舒泰神近日发布业绩预告，预计2025年净利润将出现负值。这一预测主要基于公司当前研发投入加大、市场竞争加剧及部分在研药物尚未实现商业化回报等因素。作为一家以神经损伤和自身免疫疾病治疗为核心的生物制药企业，舒泰神长期专注于创新药研发，但高强度的资金投入和较长的研发周期可能导致阶段性亏损。尽管短期利润承压，但公司核心产品如STSG-0002等仍处于临床推进阶段，未来若获批上市或将带来业绩改善。投资者需关注其研发进展及资金流动性情况，理性评估长期价值与风险。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/23447.html